A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography

Trial Profile

A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2015

At a glance

  • Drugs Iodixanol (Primary) ; Iopamidol
  • Indications Peripheral arterial disorders
  • Focus Diagnostic use
  • Sponsors GE Healthcare
  • Most Recent Events

    • 14 Apr 2014 New trial record
    • 31 Mar 2014 Results were reported in a GE Healthcare media release and were presented at the 63rd Annual Scientific Session and Expo of the American College of Cardiology (ACC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top